Minsk, Jun 7 (Prensa Latina) Cuba and Belarus analyzed possibilities of using the anti-Covid-19 Soberana and Soberana Plus immunogens developed by the Finlay Vaccine Institute, which are now recognized by the international scientific community.
During a meeting it was discussed the possibility of localizing the production of Belarusian and Cuban medicines in the territory of the two countries, expanding cooperation between pharmaceutical manufacturers.
Such an initiative would increase the mutual supply of products to improve care for the population of both nations, Belarusian Telegraphic Agency (BelTA) noted.
The parties discussed the interaction of authorized drug registration institutions to facilitate access to drugs in the two countries’ markets.
BelTA recalls that Covid-19 vaccines are approved for use in Cuba for children from three years old and adults by virtue of clinical trials, and in the case of Soberana Plus it is a universal booster immunogen.